Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout
BioPharma Dive
The deal hands Neurocrine a controversial medicine, Vykat, that achieved $190 million in sales last year but faces persistent questions about its growth trajectory and safety, according to Wall Street
pharminent
April 6, 2026 (Last updated: April 6, 2026)
BioPharma Dive
The deal hands Neurocrine a controversial medicine, Vykat, that achieved $190 million in sales last year but faces persistent questions about its growth trajectory and safety, according to Wall Street
